FindTrial
Sign In

Study on the anti-tumor effect of organic selenium-Evaluation of the curative effect of organic selenium treatment in patients with advanced colorectal cancer

Study on the anti-tumor effect of organic selenium-Evaluation of the curative effect of organic selenium treatment in patients with advanced colorectal cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042873
Enrollment
Unknown
Registered
2021-01-30
Start date
2021-02-22
Completion date
Unknown
Last updated
2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced colorectal cancer

Interventions

Control group:Placebo + capecitabine
trial group:Organic selenium + capecitabine

Sponsors

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. After first-line standard chemotherapy with 5-Fu and two drugs, the curative effect evaluation is SD, PR or CR confirmed stage IV colorectal cancer patients; 2. Serum selenium = 60 points; 4. Aged 18-75 Years; 5. Patients and their families are aware of the treatment plan of this study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Combined with severe heart, liver, lung or kidney dysfunction; 2.Combined with mental illness; 3.Combined with other tumors; 4.Patients who are intoleranc to the test drug.

Design outcomes

Primary

MeasureTime frame
Survival evaluation;—

Secondary

MeasureTime frame
Effective treatment;Quality of life evaluation;Serum selenium content;—

Countries

China

Contacts

Public ContactQing Zhang

Beijing Hospital of Traditional Chinese Medicine,Capital Medical University

zhangqingys@sina.com+86 10-52176864

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026